Jonathan W. Goldman, MD, on SCLC: Tarlatamab Extended-Interval Dosing Regimens
IASLC WCLC 2026
Jonathan W. Goldman, MD, of the University of California, Los Angeles, reviews findings from the phase II DeLLphi-309 study, which examined the efficacy, safety, and pharmacokinetics of tarlatamab extended-interval dosing regimens (20 mg every 3 weeks and 30 mg every 4 weeks) in comparison to the usual dose of 10 mg every 2 weeks in patients with small cell lung cancer (SCLC) (Abstract OA05.01).
Alexander I. Spira MD, PhD, FACP, FASCO, of Virginia Cancer Specialists and US Oncology, discusses findings from a global phase I study of izalontamab brenitecan (BL-B01D1), an antibody-drug conjugate comprising an EGFR x HER3 bispecific antibody conjugated to a novel topoisomerase 1 inhibitor payload via a stable tetrapeptide-based cleavable linker. In a randomized dose-expansion cohort, the agent demonstrated promising efficacy with a tolerable safety profile in patients with previously treated EGFR-mutated non–small cell lung cancer (NSCLC) (Abstract OA10.01).
Alexander Drilon, MD, of Memorial Sloan Kettering Cancer Center, presents efficacy and safety data from a phase II cohort of the ARROS-1 trial, which included patients with locally advanced or metastatic ROS1-positive non–small cell lung cancer (NSCLC) who were naive to tyrosine kinase inhibitor (TKI) therapy (Abstract PL03.06).
Adam J. Schoenfeld, MD, of Memorial Sloan Kettering Cancer Center, discusses findings from BNT324-01, an ongoing global phase Ib/II trial looking at pumitamig, an investigational PD-L1 × VEGF-A bispecific antibody, combined with elfetabart drozuntecan (BNT324/DB-1311), an investigational B7-H3–targeted antibody-drug conjugate, with a focus in small cell lung cancer (SCLC) (Abstract OA14.02).
Chul Kim, MD, of Georgetown Cancer Institute, reviews findings from the phase III PAPILLON study, which found that first-line amivantamab plus carboplatin/pemetrexed was associated with numerically longer overall survival compared with chemotherapy alone in patients with previously untreated advanced non–small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations (Abstract PL03.03).
Pedro Rocha, MD, PhD, of Vall d'Hebron University Hospital, presents data from the phase Ib DeLLphi-308 study, which investigated subcutaneous administration of the bispecific T-cell engager tarlatamab—which may improve convenience and produce lower peak serum concentrations, potentially reducing adverse events—compared with its usual intravenous administration among patients with extensive-stage small cell lung cancer (SCLC) (Abstract MO15.07).
